ReviewFrontiers in transplantation2026
Building pragmatic transplant immunobiology in Sri Lanka: a concise review with an LMIC lens.
Review in Frontiers in transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sri Lanka's kidney transplantation programme has matured within a resource-constrained public health system and has achieved short-term outcomes that appear comparable to published ranges from similar middle-income programmes, despite major limitations in real-time transplant immunobiology support. However, increasing recipient sensitisation, prolonged dialysis vintage, and a growing deceased-donor programme demand more reliable immunological risk assessment to improve equity and graft outcomes. This pragmatic narrative review summarises the minimum immunobiology package that can support safer kidney transplantation in low- and middle-income settings, using Sri Lanka as an example. Key concepts are explained in simple operational terms, including sensitisation and antibody screening (PRA, including the Zora assay), single-antigen bead testing and donor-specific antibody interpretation, practical use and limitations of virtual crossmatch when donor HLA data are incomplete, and the continuing role of CDC crossmatch where flow-cytometry crossmatch is unavailable. The review also highlights why unexpected early rejection may still occur even when HLA-based testing appears reassuring, and why over-reliance on any single assay can be misleading. Finally, a staged roadmap is proposed-prioritising feasible upgrades, quality assurance, workforce development, and national coordination-to progressively strengthen transplant immunobiology while preserving affordability, fairness, and sustainability. This is a pragmatic narrative review informed by consensus guidance and key peer-reviewed literature, synthesised to prioritise actionable, scalable immunobiology components for low- and middle-income settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.